Denali therapeutics inc. (DNLI)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Operating activities
Net loss

-215,385

-197,614

-66,056

-55,167

-51,554

-36,240

-136,660

-123,133

-90,543

-88,185

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

7,706

8,000

8,300

8,737

8,949

7,400

5,861

4,312

3,223

3,100

0

0

0

Stock–based compensation expense

42,289

38,378

35,135

31,744

22,740

18,791

14,602

10,220

6,569

4,409

0

0

0

Net amortization of discounts on marketable securities

4,309

5,019

4,873

4,347

3,635

2,705

2,010

1,024

-139

-753

0

0

0

Non-cash operating lease expense

944

0

6,953

6,517

2,398

3,438

-1,182

-1,339

-303

0

0

0

0

Gain on disposal of property and equipment

-

-

-

-

-

-

0

0

0

-

-

-

-

Other non-cash items

404

351

0

0

0

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other assets

-1,372

-6,675

7,099

13,868

13,828

18,290

5,303

2,911

3,499

-73

0

0

0

Accounts payable

-1,224

1,033

-1,295

-6,317

2,390

-526

1,124

7,747

-26

207

0

0

0

Accruals and other current liabilities

2,266

1,500

9,350

8,629

7,777

9,113

5,333

-248

1,264

3,578

0

0

0

Contract liabilities

-8,578

-6,286

8,870

8,856

8,047

68,777

0

0

0

-

-

-

-

Operating lease liability

0

-

-

-

0

-

-

-

-

-

-

-

-

Other non-current liabilities

-

-

-

-

-

-

-

-

-

-553

0

0

0

Net cash used in operating activities

-175,745

-151,576

-10,748

-15,135

-13,784

50,116

-61,405

-48,504

-24,249

-76,635

0

0

0

Investing activities
Purchases of marketable securities

413,041

369,696

376,432

340,273

339,704

557,930

533,775

513,319

490,876

179,789

0

0

0

Purchases of property and equipment

16,770

17,919

16,583

14,583

4,884

3,393

3,027

2,547

2,544

2,875

0

0

0

Maturities and sales of marketable securities

572,237

535,327

436,939

394,014

350,393

273,901

215,634

166,497

135,597

141,498

0

0

0

Net cash used in investing activities

142,426

147,712

43,924

39,158

5,805

-287,422

-321,168

-349,369

-357,823

-41,166

0

0

0

Financing activities
Issuance of common stock in connection with the Takeda Collaboration Agreement

-

-

-

-

-

94,406

0

0

0

-

-

-

-

Proceeds from public offering of common stock, net of issuance costs

0

-

-

-

0

-

-

-

-

-

-

-

-

Proceeds from exercise of awards under equity incentive plans

7,247

6,190

5,846

5,825

4,688

3,999

2,310

2,009

628

733

0

0

0

Net cash provided by financing activities

201,195

6,190

5,846

5,825

4,688

97,019

390,920

390,619

389,238

296,323

0

0

0

Net increase (decrease) in cash, cash equivalents and restricted cash

167,876

2,326

39,022

29,848

-3,291

-140,287

8,347

-7,254

7,166

178,522

0

0

0

Supplemental disclosures of cash flow information
Tenant improvements provided by the landlord

2

11,343

21,540

25,902

25,902

14,561

0

0

0

-

-

-

-

Property and equipment purchases accrued but not yet paid

-1,569

0

1,798

2,497

1,658

335

0

0

0

-

-

-

0

Common Stock
Payments of issuance costs related to issuance of stock

-

-

-

-

-

1,342

0

0

0

-

-

-

-

Preferred Stock
Payments of issuance costs related to issuance of stock

-

-

-

-

-

44

0

0

0

-

-

-

-